Subset of patients in which CD274 CN gains/losses did not correlate with PD-L1 IHC positivity
| Diagnosis | CD274 CN gain with PD-L1 negative (%) | N | CD274 CN loss with PD-L1 positive (%) | N |
| NSCLC (n=20 755) | 3.9 | 813 | 24.7 | 5125 |
| Urothelial carcinoma (n=1742) | 6.8 | 118 | 15.6 | 272 |
| Breast carcinoma (n=3833) | 10.0 | 384 | 12.7 | 486 |
| Cervix carcinoma (n=701) | 1.9 | 13 | 13.3 | 93 |
| Esophagus SCC (n=208) | 4.8 | 10 | 22.1 | 46 |
| HNSCC (n=655) | 0.2 | 1 | 31.0 | 203 |
| Gastric/esophageal adenocarcinoma (n=1993) | 2.0 | 39 | 36.5 | 728 |
HNSCC, head and neck SCC; IHC, immunohistochemistry; NSCLC, non-small-cell lung cance; SCC, squamous cell carcinoma.